Researchers could be closing in on a “fountain of youth” drug that can delay the effects of aging and improve the health of older adults, a new study suggests
Seniors received a significant boost to their immune systems when given a drug that targets a genetic signaling pathway linked to aging and immune function, researchers with the drug maker Novartis report.
The experimental medication, a version of the drug rapamycin, improved the seniors’ immune response to a flu vaccine by 20 percent, researchers said in the current issue of Science Translational Medicine.
The study is a “watershed” moment for research into the health effects of aging, said Dr. Nir Barzilai, director of the Institute for Aging Research at Albert Einstein College of Medicine in New York City.
Rapamycin belongs to a class of drugs known as mTOR inhibitors, which have been shown to counteract aging and aging-related diseases in mice and other animals.
Barzilai, who wasn’t involved in the study, said this is one of the first studies to show that these drugs also can delay the effects of aging in humans.
“It sets the stage for using this drug to target aging, to improve everything about aging,” Barzilai said. “That’s really going to be for us a turning point in research, and we are very excited.”
The mTOR genetic pathway promotes healthy growth in the young. But it appears to have a negative effect on mammals as they grow older, said study lead author Dr. Joan Mannick, executive director of the New Indications Discovery Unit at the Novartis Institutes for Biomedical Research.
When drugs like rapamycin are used to inhibit the effects of the mTOR pathway in mice, they “seem to extend lifespan and delay the onset of aging-related illnesses,” Mannick said.
Mannick and her colleagues decided to investigate whether a rapamycin-like drug could reverse the natural decline that elderly people experience in their ability to fight off infections.
In the clinical trial, more than 200 people age 65 and older randomly received either the experimental drug or a placebo for several weeks, followed by a dose of flu vaccine.
Flu is particularly hard on seniors, with people 65 and older accounting for nine out of 10 influenza-related deaths in the United States, according to background information provided by the researchers.
Those who received the experimental version of rapamycin developed about 20 percent more antibodies in response to the flu vaccine, researchers found. Even low doses of the medication produced an improved immune response.
The researchers also found that the group given the drug generally had fewer white blood cells associated with age-related immune decline.
Mannick called this study the “first baby step,” and was reluctant to say whether it could lead to immune-boosting medications for the elderly.
The Latest on: Anti-aging drug
via Google News
The Latest on: Anti-aging drug
- Can we end aging via science and supplements? I put it to the test - on myself - and this is what I found out.on October 7, 2020 at 2:40 pm
The quest for immortality is as old as time itself. But what can we do now to live longer, healthier lives? I embarked on a 12-week longevity experiment to see if I could alter my longevity biomarkers ...
- Global Nootropics Market Is Set To Reach USD 5,959 Million By 2024on October 7, 2020 at 8:51 am
These include supplements, drugs, and other related substances that can advance ... memory enhancement, attention and focus, anti-aging and longevity, sleep, recovery and dream enhancement, and ...
- Aging-US Releases "From Causes of Aging to Death from COVID-19"on October 7, 2020 at 6:03 am
US recently published "From Causes of Aging to Death from COVID-19" by Blagosklonny et al. which reported that COVID-19 is not ...
- US COVID-19 Vaccine Statuson October 1, 2020 at 10:22 pm
There are four vaccines that are in phase 3 clinical trials in the USA. They are * BioNTech/Pfizer vaccines * Moderna * Johnson & Johnson viral vector vaccine. * Oxford/AstraZeneca viral vector va ...
- Physicians, compounding pharmacies touting unproven drug as COVID-19 treatmenton October 1, 2020 at 12:04 pm
More than 30 medical practices and compounding pharmacies have made claims about the drug thymosin alpha-1 as a treatment for COVID-19 that are unproven, an NPR investigation found. The drug is not ...
- Web Of 'Wellness' Doctors Promote Injections Of Unproven Coronavirus Treatmenton October 1, 2020 at 3:00 am
Just as the coronavirus pandemic began its rapid and deadly spread across the United States, a well-known doctor named Dominique Fradin-Read told thousands ...
- NAD+ Metabolism in Cancer and Cancer Therapieson September 30, 2020 at 9:53 am
A focal point for metabolic changes is nicotinamide adenine dinucleotide (NAD+), where NAD+ levels in cells need to be balanced for processes to function.
- Global Antifungal Drugs Market to Surpass US$ 13,132.8 Mn by 2027, Says Coherent Market Insights (CMI)on September 30, 2020 at 7:05 am
According to Coherent Market Insights, the global antifungal drugs market is estimated to be valued at US$ 11,591.0 Mn in 2020 and is expected to exhibit a CAGR of 1.8% during the forecast period ...
- Blocking the self-destruction process of enzymes can mitigate age-related diseaseson September 29, 2020 at 10:23 pm
Stopping the cannibalistic behavior of a well-studied enzyme could be the key to new drugs to fight age-related diseases, according to a new study published online in Nature Cell Biology.
- Blocking enzyme's self-destruction process may mitigate age-related diseaseson September 29, 2020 at 9:11 am
Stopping the cannibalistic behavior of a well-studied enzyme could be the key to new drugs to fight age-related diseases, according to a new study published online in Nature Cell Biology. For the ...
via Bing News